View in browser


Drug Development Technology

 
Share this newsletter with a friend or colleague
 
Mallinckrodt begins enrolment in Phase IIa study for liver cirrhosis
image_alt

Mallinckrodt has started patient recruitment in a Phase IIa clinical trial of MNK-6106 (L-ornithine phenylacetate) for the treatment of hepatic (liver) cirrhosis and hepatic encephalopathy (HE).


Features

Covid-19 to shake up site selection decisions
Businesses looking to move operations to new geographic locations face multiple challenges in the wake of the Covid-19 pandemic.

Covid-19 forces a rethink of global supply chains


July’s top news stories
Eli Lilly reported positive findings from the Phase III MONARCH 2 clinical trial of Verzenio (abemaciclib) with fulvestrant to treat advanced or metastatic breast cancer.


Projects

Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy
Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals.

Turalio (pexidartinib) for the Treatment of Tenosynovial Giant Cell Tumour
Turalio™ (pexidartinib) is the first drug approved for the treatment of tenosynovial giant cell tumour (TGCT) in adult patients.

Baqsimi (glucagon) for the Treatment of Severe Hypoglycaemia
Baqsimi™ (glucagon) is the first nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycaemia in diabetes patients aged four years and above.


Event
Imaging in Costa Rica

25 Jul - 28 Jul

  |  Organiser: CME Science

+ ADD TO MY CALENDAR

From our partners


Press Releases

Pharmaceutical Drug Development and Particle Sizing


Industry Leaders Come on Board as NMiTE Adds Engineering Expertise
The New Model in Technology and Engineering (NMiTE) has announced three appointments to its Board of Trustees.

Sometimes, You Have to Move to Go Forward
PhenoSwitch Biosource is proud to announce that it will be operating from a new space in the beautiful Sherbrooke, Quebec, Canada.


Whitepapers

Primary Cells Isolated from Healthy Human and Animal Tissues
Caltag Medsystems has access to a large number of human and animal primary cells, sourced from a range of suppliers based in Europe and the US.

Immunoassay Technology
Gyrolab users regard this system as a must-have technology for accelerating biopharmaceutical development and production.

Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.

Thanks for reading. If you enjoyed this newsletter, please share with colleagues, friends and anybody else, get them to sign up and join the conversation. You can contact us at marketing@verdict.co.uk.

Drug Development Technology